BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong RJ, Brosgart CL, Welch S, Block T, Chen M, Cohen C, Kim WR, Kowdley KV, Lok AS, Tsai N, Ward J, Wong SS, Gish RG. An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States. Hepatology 2021;74:607-26. [PMID: 33655536 DOI: 10.1002/hep.31782] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Robinson A, Wong R, Gish RG. Chronic Hepatitis B Virus and Hepatitis D Virus: New Developments. Clin Liver Dis 2023;27:17-25. [PMID: 36400464 DOI: 10.1016/j.cld.2022.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Vincent JP, Nyamasege C, Wang S, Madec Y, Shimakawa Y. Prevalence of hepatitis B, C, and D virus infection in Haiti: A systematic review and meta-analysis. Front Public Health 2022;10:1099571. [PMID: 36711383 DOI: 10.3389/fpubh.2022.1099571] [Reference Citation Analysis]
3 Da BL, He AR, Shetty K, Suchman KI, Yu H, Lau L, Wong LL, Rabiee A, Amdur RL, Crawford JM, Fox SS, Grimaldi GM, Shah PK, Weinstein J, Bernstein D, Satapathy SK, Chambwe N, Xiang X, Mishra L. Pathogenesis to management of hepatocellular carcinoma. Genes Cancer 2022;13:72-87. [DOI: 10.18632/genesandcancer.226] [Reference Citation Analysis]
4 Wong RJ, Kaufman HW, Niles JK, Chen C, Yang Z, Kapoor H, Cheung R, Gish RG. Low Performance of Hepatitis Delta Virus Testing Among 2 National Cohorts of Chronic Hepatitis B Patients in the United States. Am J Gastroenterol 2022;117:2067-70. [PMID: 35971233 DOI: 10.14309/ajg.0000000000001947] [Reference Citation Analysis]
5 Silliman M, Alber JM, Gib S, Gee M, Conover S, Chan C, Cohen C, Freeland C, Racho R. Comparing lengths and inclusion of information in storytelling videos: Implications for Hepatitis B education. PEC Innovation 2022;1:100049. [DOI: 10.1016/j.pecinn.2022.100049] [Reference Citation Analysis]
6 Papatheodoridi M, Papatheodoridis GV. State-of-the-art and emerging antivirals for chronic hepatitis B infection. Expert Opinion on Pharmacotherapy 2022. [DOI: 10.1080/14656566.2022.2144219] [Reference Citation Analysis]
7 Nguyen MH, Roberts LR, Engel-Nitz NM, Bancroft T, Ozbay AB, Singal AG. Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States. Hepatol Commun 2022;6:3443-56. [PMID: 36178256 DOI: 10.1002/hep4.2087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zou Z, Zhang Z, Lu C, Wang H. Comparison of time trends in the incidence of primary liver cancer between China and the United States: an age-period-cohort analysis of the Global Burden of Disease 2019. Chin Med J (Engl) 2022;135:2035-42. [PMID: 36103990 DOI: 10.1097/CM9.0000000000001980] [Reference Citation Analysis]
9 Wong RJ, Kaufman HW, Niles JK, Meyer WA 3rd, Chitnis AS. Prevalence of Hepatitis B Virus and Latent Tuberculosis Coinfection in the United States. J Public Health Manag Pract 2022;28:452-62. [PMID: 35867500 DOI: 10.1097/PHH.0000000000001536] [Reference Citation Analysis]
10 Sucher AJ, Sucher BJ, Chahine EB. PreHevbrio: A New 3-Antigen Hepatitis B Vaccine for Adults. Ann Pharmacother 2022;:10600280221114469. [PMID: 35906803 DOI: 10.1177/10600280221114469] [Reference Citation Analysis]
11 Jacobson IM, Brown RS Jr, McMahon BJ, Perrillo RP, Gish R. An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus. J Clin Gastroenterol 2022;56:478-92. [PMID: 35389923 DOI: 10.1097/MCG.0000000000001695] [Reference Citation Analysis]
12 Shamaa O, Mendiratta V, Trudeau S, Gordon SC. Evolving Screening and Vaccination Recommendations for Hepatitis B in the USA. Curr Hepatology Rep 2022;21:37-43. [DOI: 10.1007/s11901-022-00583-3] [Reference Citation Analysis]
13 Weng MK, Doshani M, Khan MA, Frey S, Ault K, Moore KL, Hall EW, Morgan RL, Campos-Outcalt D, Wester C, Nelson NP. Universal hepatitis B vaccination in adults aged 19-59 years: Updated recommendations of the advisory committee on immunization practices-United States, 2022. Am J Transplant 2022;22:1714-20. [PMID: 35674154 DOI: 10.1111/ajt.16661] [Reference Citation Analysis]
14 Chen MS, Lee RJ, Madan RA, Ta Park V, Shinagawa SM, Sun T, Gomez SL. Charting a Path Towards Asian American Cancer Health Equity: A Way Forward. J Natl Cancer Inst 2022:djac055. [PMID: 35437573 DOI: 10.1093/jnci/djac055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Weng MK, Doshani M, Khan MA, Frey S, Ault K, Moore KL, Hall EW, Morgan RL, Campos-Outcalt D, Wester C, Nelson NP. Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:477-83. [PMID: 35358162 DOI: 10.15585/mmwr.mm7113a1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
16 Choi YH, Lee HW, Purdy MA. Natural antibody IgG levels are associated with HBeAg-positivity and seroconversion in chronic hepatitis B patients treated with entecavir. Sci Rep 2022;12:4382. [PMID: 35288624 DOI: 10.1038/s41598-022-08457-w] [Reference Citation Analysis]
17 Emeasoba EU, Omarufilo F, Bosah JN, Sigal SH. Breaking down barriers for hepatitis B screening in the Bronx West African community through education in collaboration with faith-based organizations: A cohort study. The Lancet Regional Health - Americas 2022;7:100120. [DOI: 10.1016/j.lana.2021.100120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Yasseen AS, Kwong JC, Feld JJ, Kustra R, MacDonald L, Greenaway CC, Janjua NZ, Mazzulli T, Sherman M, Lapointe-Shaw L, Sander B, Crowcroft NS. The viral hepatitis B care cascade: A population-based comparison of immigrant groups. Hepatology 2022;75:673-89. [PMID: 34537985 DOI: 10.1002/hep.32162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ramrakhiani NS, Chen VL, Le M, Yeo YH, Barnett SD, Waljee AK, Zhu J, Nguyen MH. Optimizing hepatitis B virus screening in the United States using a simple demographics-based model. Hepatology 2022;75:430-7. [PMID: 34496066 DOI: 10.1002/hep.32142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Gish RG, Asselah T, Squires K, Mayers D. Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens. Antivir Chem Chemother 2022;30:204020662211387. [DOI: 10.1177/20402066221138705] [Reference Citation Analysis]
21 Wong RJ, Cheung RC. Real-World Safety and Effectiveness of Oral Nucleos(t)ide Analogs in the Treatment of Chronic Hepatitis B Virus Infection. Curr Hepatology Rep 2021;20:144-150. [DOI: 10.1007/s11901-021-00571-z] [Reference Citation Analysis]
22 Freeland C, Racho R, Kamischke M, Moraras K, Wang E, Cohen C, Kendrick S. Health-related quality of life for adults living with hepatitis B in the United States: a qualitative assessment. J Patient Rep Outcomes 2021;5:121. [PMID: 34757456 DOI: 10.1186/s41687-021-00398-8] [Reference Citation Analysis]
23 Freeland C, Racho R, Kamischke M, Moraras K, Wang E, Cohen C. Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment. J Viral Hepat 2021;28:1539-44. [PMID: 34363715 DOI: 10.1111/jvh.13592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Chak E, Vu F, Dang J, Smith U, Stewart S, Tam K, Beste-Fong A, Phelps B, Johnson I, Suarez M, Pat Pauly M, Chen MS Jr. Enhancing Electronic Health Systems to End Transmission of Chronic Hepatitis B During COVID-19: A Collaborative Approach. Clin Liver Dis (Hoboken) 2021;17:424-8. [PMID: 34386208 DOI: 10.1002/cld.1144] [Reference Citation Analysis]
25 Toy M, Hutton D, Harris AM, Nelson N, Salomon JA, So S. Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States. Clin Infect Dis 2021:ciab405. [PMID: 33956937 DOI: 10.1093/cid/ciab405] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
26 Ward JW. Hepatitis B Vaccines. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]